View Older Stories View More Recent Stories
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Contineum Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
LB Pharmaceuticals raises $100 million in private placement
-
Adlai Nortye raises $140 million in private placement financing
-
Crescent Biopharma raises $185 million, partners with Kelun-Biotech
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Spirit AeroSystems Holdi Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Camping World Holdings, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Avalo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting
-
Opus Genetics raises $23 million in registered direct offering
-
Tango Therapeutics raises $225 million in stock offering
-
Expedia Group names Rob Bevegni as VP of investor relations
-
Minerva Neurosciences secures up to $200 million for schizophrenia drug trial
-
Lexeo Therapeutics closes $153.8 million public offering and private placement
-
Lexeo Therapeutics prices $135 million public offering at $8 per share
-
Lexeo Therapeutics launches stock offering and private placement
-
Ovid Therapeutics raises up to $175 million in private placement
-
CAMP4 raises up to $100 million for SYNGAP1 disorder treatment
-
CAMP4 raises up to $100 million for SYNGAP1 disorder treatment
-
iBio closes $50 million public offering led by Balyasny
-
Form SCHEDULE 13G/A Shapeways Holdings, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Camping World Holdings, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Spirit AeroSystems Holdi Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
F.N.B. Corp's (FNB) First National Bank names Chris Chan as CSO
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Hudson Pacific Propertie Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Shapeways Holdings, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
StandardAero (SARO) appoints Rama Bondada as VP of Investor Relations
-
Senti Biosciences (SNTI) Strengthens Leadership Team with Strategic Hires
-
Form SCHEDULE 13G Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A LEAP THERAPEUTICS, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Hudson Pacific Propertie Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Shapeways Holdings, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Five9 (FIVN) Appoints Sagar Gupta to Board of Directors
-
Form SC 13G/A Shapeways Holdings, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SC 13G LEAP THERAPEUTICS, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SC 13G/A WW INTERNATIONAL, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.

